An Advisor Friendly HSA Solution
PEORIA, IL / ACCESSWIRE / April 3, 2019 / MyHSA announced a strategic partnership and collaboration today, debuting a truly...
user
NeoGenomics to Present at 18th Annual Needham & Company Health Care Conference
FT. MYERS, FLORIDA / ACCESSWIRE / April 2, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic...
GeneNews Closes CDN $510,000 Second Tranche of Strategic Private Placement
TORONTO, ON / ACCESSWIRE / April 2, 2019 / GeneNews Limited (TSX: GEN) ("GeneNews" or the "Company") today announced that...
Orchestra BioMed(TM) to Present at the 2019 Bioelectronic Medicine Forum
Panel presentation will provide an overview and outlook on BackBeat Cardiac Neuromodulation Therapy, a potent, novel bioelectronic treatment for hypertension...
Easton Announces Signing of Joint Venture Agreement for the Purchase and Development of 9 Townhomes with Revenue in Excess of $4 Million and Provides Update on its Framing Contract with Revenues of $770K for Q1
TORONTO, ON / ACCESSWIRE / April 2, 2019 / Easton Pharmaceuticals Inc. (OTC PINK: EAPH) Announces that is has signed...
Heat Biologics Delivers Poster Presentation at the AACR Annual Meeting 2019
Animal Study Demonstrates Combination of HS-110 and HS-130 Yields Three-Fold Increase in Anti-Tumor CD8+ T-cell Expansion DURHAM, NC / ACCESSWIRE...
Savara to Present at the H.C. Wainwright Global Life Sciences Conference in London
AUSTIN, TX / ACCESSWIRE / April 2, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced...
NanoVibronix Provides Year-End Business Update
Reports on Commercial Progress for both PainShield® and UroShield® ELMSFORD, NY / ACCESSWIRE / April 2, 2019 / NanoVibronix, Inc.,...
Dthera Sciences Announces Pursuit of Strategic Transaction
SAN DIEGO, CA / ACCESSWIRE / April 2, 2019 / Dthera™ Sciences (OTCQB: DTHR) a leading digital therapeutic company specializing...
Patient Six Cancer-Free Twelve Months After Single Anti-Cancer Treatment
Results of Phase Ib Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study Demonstrate a 66% Complete Response ("CR") at the Therapeutic...
Milestone Scientific Reports 70% Year-Over-Year Revenue Growth and Positive Net Income for the Fourth Quarter of 2018
LIVINGSTON, NJ / ACCESSWIRE / April 2, 2019 / Milestone Scientific Inc. (NYSE American: MLSS), a leading developer of computerized...
Genmed appoints Nicky Carless as national sales manager
April 2, 2019 – Genmed, a specialist provider of vendor neutral managed services to the NHS, today announces the appointment...
Gateshead Health extends use of BridgeHead’s HealthStore®
BridgeHead’s Independent Clinical Archive will now house all medical images across the TrustASHTEAD, UK – 2 April 2019 – As...
Jaguar Health Subsidiary Napo Pharmaceuticals Issues Further Regulatory Update Regarding Potential Follow-on Indication for Mytesi
SAN FRANSISCO, CA / ACCESSWIRE / April 2, 2019 / Napo Pharmaceuticals, Inc. (Napo), a human health company developing and...
Dr. Sarah Fakih joins MorphoSys as Head of Corporate Communications and Investor Relations
PLANEGG/MUNICH GERMANY / ACCESSWIRE / April 1, 2019 / Dr. Sarah Fakih joined MorphoSys AG (FSE: MOR; Prime Standard Segment,...
Kadmon Announces Appointment of Arthur Kirsch to Board of Directors
NEW YORK, NY / ACCESSWIRE / April 1, 2019 / Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Arthur Kirsch...
ReShape Lifesciences Announces Fourth Quarter and Full Year 2018 Financial Results
SAN CLEMENTE, CA / ACCESSWIRE / April 1, 2019 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive...
NHS doctors train using virtual reality to improve care for people with diabetes
The NHS England diabetes team has partnered with Oxford Medical Simulation to train doctors using virtual reality. Doctors can now...
Experion Completes First Shipment to the Province of Saskatchewan
CALGARY, AB / ACCESSWIRE / April 1, 2019 / Viridium Pacific Group Ltd. ("Viridium" or the "Company") (TSXV: VIR) (OTC...
Positive Pilot Phase 3 Data Position VistaGen’s PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Needed Treatment for Social Anxiety Disorder
PH94B has potential to be the First FDA-Approved PRN Treatment for Social Anxiety Disorder New Findings Presented at the 2019...